Loïc Bergougnoux

Capecitabine plus oxaliplatin (XELOX) <i>versus</i> 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

Michel Ducreux, Jaafar Bennouna, Mohamed Hebbar et al. · International Journal of Cancer · 2010 · 169 citations

Medicine, Oncology, Pharmacology +10

Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study

Jean-Marc Extra, Eric C. Antoine, Anne Vincent‐Salomon et al. · The Oncologist · 2010 · 110 citations · Full text

Medicine, Oncology, Pharmacology +11

Single Treatment with Rituximab Monotherapy for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with Extended Follow-Up (F/Up) of 7 Years.

Philippe Colombat, Nicole Brousse, Franck Morschhauser et al. · Blood · 2006 · 50 citations

Medicine, Immunology, Oncology +9

Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas® 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting

Samia Mourah, Marc G. Denis, Fabienne Escande Narducci et al. · PLoS ONE · 2015 · 28 citations · Full text

Medicine, Oncology, Cancer Genetics +12

Single 4-Dose Rituximab Treatment for Low-Tumor Burden Follicular Lymphoma (FL): Survival Analyses with a Follow-Up (F/Up) of at Least 5 Years.

Philippe Solal‐Céligny, Gilles Salles, Nicole Brousse et al. · Blood · 2004 · 21 citations

Medicine, Oncology, Pharmacotherapy +6